healiva® is a patient centric Biotech company, delivering precision medicine to improve people’s quality of life. We are the first Biotech offering multiple end-to-end, intuitive wound care solutions that could be personalized whilst remaining affordable. Wound healing is the intricate process and the biological complexity of this sequence of events means that despite the majority of superficial wounds heal without issue, this process can go awry resulting in a non-healing, chronic wound. These can take months, even years to heal with current treatment approaches. Non-healing, chronic wounds represent a significant burden to both patients’ quality of life and to healthcare systems. About 60% of chronic wounds remain unhealed. In the EU, between 1.5 and 2m people are living with chronic wounds, with Switzerland alone being home to over 300,000. For the 60 million diabetics in Europe, over 5% will develop a foot wound which if left untreated can lead to amputation. Starkly, this consequence is also on the rise, with limb amputation increasing by nearly 20% between 2014-2017 when compared to 2010-2013. Healiva®’s pipeline products are poised to reduce the cost to heal a wound by addressing these factors directly, providing solutions that are not only highly effective, but also easy-to-use, cost-effective, and accessible.
Our customer base is multifaceted, encompassing hospitals, medical practitioners, insurance providers, and the patients themselves. Healiva’s pipeline products will target key pain-points for our customers, including the high-cost of care, the time to heal, the requirement for frequent dressing changes and specialist medical expertise, whilst reducing wounds reoccurrence to allow patients to re-establish their normal work/life routines.
The wound care market stands at €15.8b in 2021, growing at a CAGR of 7.6% to 2026. The Enzymatic debridement segment alone (healiva 003) accounts for €0.58b annually. • Nearly 15% of Medicare beneficiaries (8.2m) have more than one type of wound, or a wound-related infection, accounting for annual direct spending of >$28.1B in the USA.
Healiva® is looking for financial and strategic investors – we are open for ordinary shares and equity against shares, and giving Board member positions. Current investment will be injected to fast track healiva 003 & healiva 004 to market within 3 – 4 years (staff, clinical development, prototyping, and market launch activities). healiva is open to partner with long term strategic players.
healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano combining digital health, enzyme technology and cell therapy to deliver personalised and precision solutions for regenerative biology.